Combination Immunotherapies

• 3786 · PDF Peripheral immune signature of dostarlimab in addition to standard of care definitive radiation in patients with medically inoperable endometrial cancer Liyun Chen, Rachel Furuya, Linda Odibo, Lulu Sun, David Mutch, Carolyn McCourt, Matthew A. Powell, Julie K. Schwarz, Jessika A. Contreras, Premal H. Thaker, Stephanie Markovina
• 3787 · PDF The safety of PARP inhibitors combined with immune checkpoint inhibitors versus immune checkpoint inhibitor monotherapy: A systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials Mus'ab Theeb Mustafa, Aws Khalid Abushanab, Ahmad Yousef Alazzam, Mahmoud Taysir Mousa, Ahmad Sa'ed, Noor N. Al-Bzour, Osama Wadah Rammaha, Zaher Mutaz Ashour, Hamza Muneer Alakhras, Yihea Mohammad Al-Mashaqbah, Ahmad Sami Othman, Nour Maher Mustafa, Renad Fawwaz Al Banawi, Anwaar Saeed
• 3788 · PDF Integrated single-cell analysis identifies biomarkers associated with clinical benefit in patients with PD-L1 positive, advanced NSCLC treated with SBRT followed by atezolizumab plus tiragolumab Jii Bum Lee, Dong Kwon Kim, Sang Hoon Lee, Kyung Hwan Kim, Su-Jin Choi, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
• 3789 · PDF Treatment with ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, combined with anti-PD-L1 induces complete tumor regression with durable immune memory Taronish Dubash, Joelle Baddour-Sousounis, Amira Elbakry, Jessica Hopkins, Subodh Kumar, Yingchun Spring Liu, Ahmed Youssef, Kate Rappard, Ignacio Arribas Diez, Georgia Mista, Marc Isaksson, Francisco Santana, Luka Romero, Zachary Best, Nina Lipjankic, Anna-Maria Alves, Daphne García-López, Portia Lombardo, Calvin Yang, Emma Ahrman, Valentina Siino, Magnus E. Jakobsson, Helen Nilsson, Ayesha Murshid, Lei Shi, Caroline Wigerup, Michail Shipitsin, Joon Jung, David Proia, Kristina Masson, Peter Blume-Jensen
• 3790 · PDF Combined inhibition of myeloid cell PI3Kgamma and regulatory T cell integrin alphavbeta8 promotes durable tumor suppression Erpei Wang, Giuliana Mognol, MOHAMMAD AMJAD, Hui Chen, Mark Paradise, Dean Sheppard, judith Varner
• 3791 · PDF Cry1 inhibition reverses resistance to T cell-based immunotherapy by promoting anti-tumor immunity Tae Woo Kim, Oh Se Jin
• 3792 · PDF EGFR promotes immune evasion and resistance to immunotherapy in NF1 mutant melanoma Milad Ibrahim, Irineu Illa-Bochaca, Tara Muijlwijk, Ines Delclaux, KATHERINE VENTRE, George Jour, Shi Qiu, Agrima Dutt, Paola Angulo salgado, Amanda W. Lund, Markus Schober, Iman Osman
• 3793 · PDF Preventing nk cell activation in the damaged liver induced by cabozantinib/pd-1 blockade increases survival in hepatocellular carcinoma models Satoru Morita, Tomofumi Ando, Hiroto Kikuchi, Atsuyo Morita, Tatsuya Kobayashi, Grace Birch, Ryota Tanaka, Aya Matsui, Zhiping Ruan, Peigen Huang, Alexei Hernandez, Erin M. Coyne, Sarah M. Shin, Robin Kate Kelley, Mark Yarchoan, Stefan Halvorsen, Slim Sassi, Mari Mino Kenudson, Shadmehr Demehri, Rizwan Romee, Won Jin Ho, Dan Duda
• 3794 · PDF ACR246, a first-in-class 5T4 antibody-drug conjugate (ADC), showed promising anticancer efficacy in preclinical models and patient with esophageal cancer Xi Jiao, Zhenwei Miao, Na Zhuo, Panpan Zhang, Jifang Gong, Feng Wang, Yan Dai, Li Yang, Wu Yao, Shanhui Weng, Johannes Nippgen, Lin Shen
• 3795 · PDF Crept-618: First GalNAc-siRNA targeting CREPT reverses HCC immune evasion and synergizes with anti-PD-1 Jianghua Li, Alex Zou, He Yang, Jiayu Wang, Weihua Yang, Zhijie Chang, Jun Li
• 3796 · PDF Targeting midkine with HBS-101 enhances chemotherapy and immunotherapy response in TNBC via immune activation and oncogenic pathway suppression Baskaran Subramani, Megharani R. Mahajan, Panneerdoss Subbarayalu, Zhenming Xu, Neelam Mukherjee, Gangadhara R. Sareddy, Hareesh B. Nair, Ratna K. Vadlamudi, Suryavathi Viswanadhapalli
• 3797 · PDF A novel tritherapy overcoming the immune suppressive tumor microenvironment elicits robust antitumor activity Brian G. Morreale, Andrea Monell, Han Yu, David B. Sykes, Jonathan F. Lovell, Michael J. Nemeth, Scott I. Abrams
• 3798 · PDF In vivo results of AGX101, a TM4SF1-directed tubulin inhibitor conjugate, in combination with immune checkpoint inhibitors Shou-Ching Jaminet, Paul Jaminet, Glen J. Weiss
• 3799 · PDF HER3 inhibition sensitizes metastatic colorectal and pancreatic cancer to immunotherapy Chao Wei, Moeez Ghani Rathore, Elizabeth Bryson, Kimberly Curry, Jennifer Baek, Jordan M. Winter, Rui Wang
• 3800 · PDF Combinational effects of VC2-GMCSF oncolytic virus and paclitaxel in end-stage breast cancer animal model Reza Ghavimi, Leila Rahimian, Vladimir Chouljenko, Harikrishnan Mohan, Ojasvi Dutta, Md Mehedi Hasan, Jeongha Lee, Minori Kojima, Jose Sezar Menk, Konstantin Kousoulas
• 3801 · PDF Synergistic therapy by combination of a plant virus immunomodulator and IL-12 against murine ovarian cancer Xinyi Deng, Jessica Fernanda Affonso de Oliveira, Nicole F. Steinmetz
• 3802 · PDF Adaptive cd73 upregulation undermines parp inhibitor efficacy and creates a therapeutic opportunity for combined blockade in advanced prostate cancer Ping xie, Jie Fan, Hui Tang, Longzhen Song, Bin Zhang
• 3803 The unique presentation of four immunotherapy toxicities in a single patient Orianna Guarisma-Lugo, Roderick Brice, Samuel Ramirez, Winston W. Tan
• 3804 Engineering CAR macrophages in combination with anti-tumor therapies to suppress brain metastasis Shih-Ying Wu, Abhishek Tyagi, Eleanor Cecile Smith, Ravindra Pramod Deshpande, Jee Won Kim, Kounosuke Watabe
• 3805 Enhancing anti-tumor immunity via in vivo LNP delivery of a universal chimeric adapter protein to activate innate immune cells through T cell engagers Kevin Carbajal, Warren Anderson, Matthias Schroff, Maximilian Richter
• 3807 · PDF Engineering and preclinical development of a differentiated EGFR/PDL1 bispecific ADC for the targeted therapy of solid tumors Liang Zhu, Chen Chuan, Mei Tian, Dandan Liu, Jiyuan Tian, Lisha Dong, Yongxin Shang, Rongmei Yan, Kezhen Ye, Liang Tian, Jian Peng, Zhenping Zhu
• 3808 · PDF Regulation of PD-L1 + tumor associated macrophages by collagen expressing myCAFs and luminal progenitors in endocrine-resistant breast cancer Nirmal Das, Cheng-Han Hsieh, Rumela Chakrabarti
• 3809 · PDF Bax activation promotes immune activity and synergizes with PD-L1 blockade immunotherapy against mutant KRAS-driven lung cancer Abu Syed Md Anisuzzaman, Xingming Deng
• 3810 · PDF Intratumoral (IT) ruxotemitide (LTX‑315) in combination with pembrolizumab in patients with unresectable advanced melanoma refractory to PD-1/PD-L1 therapy: Final results from the ATLAS-IT-05 study Stéphane Dalle, Adi Diab, John M. Kirkwood, Miguel F. Sanmamed, Laurent Mortier, Marta Nyakas, Thomas Urban Marron, Maciej Gil, Øystein Rekdal, Karim A. Benhadji, Caroline Robert
• 3811 · PDF Exploring immunomodulatory tumor-derived vaccines targeting triple negative breast cancer cells Marcio C. Bajgelman, Karina Thomaz, Daniela Mizobuti, Susana Ramalho, Sophie Derchain
• 3812 · PDF A novel 'Seed-and-Boost' immunotherapy drives potent TCR-T cell expansion, tumor infiltration, and durable tumor control Kar Wai Tan, Kan Xing Wu, Jin Wei Tan, Melissa Wirawan, Yovita Purwanti, Ana Dios, Fan Zhao, Natasha Girgis, Alessandra Nardin, Evan W. Newell, Anish Suri, Steven N. Quayle, Michael Fehlings
• 3813 · PDF Synergistic immunomodulation by Tumor Treating Fields combined with immunotherapy across solid tumors: A systematic review with translational relevance to pancreatic ductal adenocarcinoma. Douaa Albelal, Hari Krishnareddy Rachamala, Hani Babiker

在完整检索应用中浏览本分会场 →